Terms: = Lung cancer AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C AND Diagnosis
5 results:
1. Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic lung Adenocarcinoma.
Yang G; Kim KH; Lee CG; Hong MH; Kim HR; Cho Y; Yoon HI
Cancer Res Treat; 2024 Jan; 56(1):115-124. PubMed ID: 37641819
[TBL] [Abstract] [Full Text] [Related]
2. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract] [Full Text] [Related]
3. Imaging and its Impact on Defining the Oligometastatic State.
Pirasteh A; Lovrec P; Pedrosa I
Semin Radiat Oncol; 2021 Jul; 31(3):186-199. PubMed ID: 34090645
[TBL] [Abstract] [Full Text] [Related]
4. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature.
Schanne DH; Heitmann J; Guckenberger M; Andratschke NHJ
Cancer Treat Rev; 2019 Nov; 80():101892. PubMed ID: 31522079
[TBL] [Abstract] [Full Text] [Related]
5. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract] [Full Text] [Related]